New Japan malaria vaccine cuts infections 'by 72%'

A team of Japanese researchers say they have developed a vaccine that cuts the risk of malaria developing in humans by more than two-thirds.

The disease, which is carried by parasite-bearing , kills around 650,000 people each year, mostly African children under five, according to the UN's (WHO).

While there are a number of preventative medicines already in use, scientists say drug-resistance is growing.

Researchers from Osaka University have developed a dry powder vaccine, called BK-SE36, from a genetically-modified protein found inside the parasite, which they mixed with aluminum hydroxyl gel.

"The vaccine's effect is greater than those hitherto reported of any other antimalaria vaccines," a statement issued this week said, adding BK-SE36 is expected to reduce markedly the number of deaths caused by the mosquito-borne disease.

The vaccine has already undergone trials on adults in Japan and was also tested in a malaria-endemic area in northern Uganda between 2010 and 2011. Neither study found any safety problems.

A follow-up study of people in Uganda, aged between six and 20, found the vaccine lowered the number of people infected by malaria by 72 percent.

The findings were published on Tuesday on the online US science journal PLOS One, according the statement.

BK-SE36 far outperformed the 31 percent decline achieved by another new vaccine developed by a British company, the statement said.

Professor Toshihiro Horii, who led the study, told Jiji Press he wants to put BK-SE36 to practical use "in five years after conducting a clinical trial on infants between zero and five, who account for the bulk of malaria deaths."

The study came as a non-profit group said Friday it was launching a project to comb the catalogues of some of Japan's biggest drug companies in the hunt for treatments for diseases that kill thousands of people every year.

The Fund (GHIT Fund), set up by the Japanese government, Japanese pharma companies and the Bill & Melinda Gates Foundation, said they were looking at a potential five-year commitment of more than $100 million to support research and development into neglected diseases.

The project will see researchers looking through the libraries of compounds held by drug companies to see what possible treatments they contain for tuberculosis, malaria, and other illnesses that threaten hundreds of millions of people in the developing world.

The announcement was made on the sidelines of the five-yearly Tokyo International Conference on African Development (TICAD) which will see Japan welcome heads of government from up to 40 African countries.

add to favorites email to friend print save as pdf

Related Stories

Japan-backed fund unveils TB, malaria therapy search

May 31, 2013

A non-profit group said Friday it was launching a project to comb the catalogues of some of Japan's biggest drug companies in the hunt for treatments for diseases that kill thousands of people every year.

Malaria vaccine fails to work after four years

Mar 20, 2013

A new vaccine that has raised hopes of becoming a potent new tool in the battle against malaria seems to stop working in children after four years, according to research published Wednesday.

India announces low-cost rotavirus vaccine (Update)

May 14, 2013

The Indian government announced Tuesday the development of a new low-cost vaccine proven effective against a diarrhea-causing virus that is one of the leading causes of childhood deaths across the developing world.

Malaria's severity reset by mosquito

May 30, 2013

(Medical Xpress)—For the first time, researchers have proven that the way in which malaria is transmitted to the host affects how severe the resulting infection will be.

Recommended for you

Sierra Leone, Liberia brace for new Ebola cases

3 hours ago

Two of the West African nations hardest hit by Ebola were bracing for new caseloads on Monday after trying to outflank the outbreak with a nationwide checkup and a large new clinic.

Reversing the effects of pulmonary fibrosis

4 hours ago

Yale University researchers are studying a potential new treatment that reverses the effects of pulmonary fibrosis, a respiratory disease in which scars develop in the lungs and severely hamper breathing.

Streets bustling after Sierra Leone shutdown ends

10 hours ago

Streets in Sierra Leone's capital bustled again Monday after an unprecedented nationwide shutdown during which officials said more than 1 million households were checked for Ebola patients and given information ...

User comments